Semaglutide and tirzepatide have among the most thoroughly documented side effect profiles of any peptide discussed on this site, precisely because their large trial programs and years of post-market use have generated real safety data at scale.
The Most Common Effects
Gastrointestinal symptoms dominate the side effect profile for both drugs: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are most pronounced during dose escalation, the gradual increase used specifically to improve tolerability, and tend to lessen over time for many patients, though they're also the leading reason patients discontinue treatment in trials.
Less Common but Notable Effects
Both drugs can cause reduced appetite (part of their intended mechanism), fatigue, and, less commonly, gallbladder-related issues including gallstones. Injection site reactions, redness, itching, or mild swelling, are also reported, generally mild and transient.
Serious but Rarer Risks
Pancreatitis (inflammation of the pancreas) has been reported in association with GLP-1 drugs, and both labels advise discontinuation if pancreatitis is suspected. Both carry the boxed warning regarding thyroid C-cell tumors observed in rodent studies, discussed in more detail in this site's dedicated article on boxed warnings.
Who Should Be Particularly Cautious
The labels specifically flag caution for patients with a history of diabetic retinopathy (semaglutide has been associated with a documented, though still-studied, risk of worsening retinopathy in some patients with pre-existing diabetic eye disease), and for those with a history of pancreatitis.
Why Documentation Quality Matters Here
Because these effects come from large trials and extensive post-market surveillance rather than scattered anecdotal reports, this side effect list is considerably more reliable and complete than what's available for most other peptides on this site, an important reminder that a longer, more specific list of documented side effects often reflects better safety monitoring, not necessarily a more dangerous drug.
The Bottom Line
Anyone starting either medication should review the full prescribing information with their physician, since individual risk factors, other medications, and personal and family medical history all affect how this general side effect profile applies to a specific person.
How Side Effect Rates Were Actually Measured
The side effect percentages reported in each drug's prescribing information come directly from the controlled trial data discussed in this site's research section, comparing rates in the treatment group against the placebo group, which allows a more accurate picture of what's actually attributable to the drug versus what would have occurred anyway in a similar population. This is a meaningfully more rigorous way of establishing a side effect profile than the informal pattern-matching that anecdotal reports alone can offer.